CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
05 2019
Historique:
received: 27 11 2018
accepted: 04 04 2019
entrez: 31 5 2019
pubmed: 31 5 2019
medline: 8 11 2019
Statut: epublish

Résumé

Epstein Barr virus (EBV) is one of the most ubiquitous human pathogens in the world, persistently infecting more than 90% of the adult human population. It drives some of the strongest human CD8+ T cell responses, which can be observed during symptomatic primary infection known as infectious mononucleosis (IM). Despite high viral loads and prolonged CD8+ T cell stimulation during IM, EBV enters latency and is under lifelong immune control in most individuals that experience this disease. We investigated whether changes in T cell function, as frequently characterized by PD-1 up-regulation, occur during IM due to the prolonged exposure to high antigen levels. We readily detected the expansion of PD-1 positive CD8+ T cells together with high frequencies of Tim-3, 2B4, and KLRG1 expression during IM and in mice with reconstituted human immune system components (huNSG mice) that had been infected with a high dose of EBV. These PD-1 positive CD8+ T cells, however, retained proliferation, cytokine production, and cytotoxic abilities. Multiple subsets of CD8+ T cells expanded during EBV infection, including PD-1+Tim-3+KLRG1+ cells that express CXCR5 and TCF-1 germinal center homing and memory markers, and may also contain BATF3. Moreover, blocking the PD-1 axis compromised EBV specific immune control and resulted in virus-associated lymphomagenesis. Finally, PD-1+, Tim-3+, and KLRG1+ CD8+ T cell expansion coincided with declining viral loads during low dose EBV infection. These findings suggest that EBV infection primes PD-1 positive CD8+ T cell populations that rely on this receptor axis for the efficient immune control of this ubiquitous human tumor virus.

Identifiants

pubmed: 31145756
doi: 10.1371/journal.ppat.1007748
pii: PPATHOGENS-D-18-02269
pmc: PMC6542544
doi:

Substances chimiques

Cytokines 0
Inflammation Mediators 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007748

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nature. 2012 Oct 25;490(7421):502-7
pubmed: 22992524
Annu Rev Pathol. 2014;9:349-72
pubmed: 24111911
J Immunol. 1987 Dec 1;139(11):3802-7
pubmed: 3119718
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
J Infect Dis. 2005 Mar 15;191(6):985-9
pubmed: 15717276
N Engl J Med. 2010 May 27;362(21):1993-2000
pubmed: 20505178
J Infect Dis. 2005 Nov 1;192(9):1505-12
pubmed: 16206064
Annu Rev Immunol. 2007;25:587-617
pubmed: 17378764
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
J Exp Med. 2012 Mar 12;209(3):471-8
pubmed: 22393125
J Clin Invest. 2015 Jan;125(1):304-15
pubmed: 25485679
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
PLoS Pathog. 2015 Dec 01;11(12):e1005286
pubmed: 26624012
Haematologica. 2010 Dec;95(12):2080-7
pubmed: 20823128
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Semin Cancer Biol. 2008 Dec;18(6):381-7
pubmed: 18996483
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Eur J Immunol. 2001 Mar;31(3):677-86
pubmed: 11241270
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Cell. 2009 Jul 10;138(1):30-50
pubmed: 19596234
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754
pubmed: 29654146
Front Immunol. 2018 Feb 12;9:238
pubmed: 29483919
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
J Exp Med. 2015 Jun 29;212(7):1125-37
pubmed: 26034050
J Exp Med. 2009 Jun 8;206(6):1423-34
pubmed: 19487422
PLoS Pathog. 2016 May 17;12(5):e1005642
pubmed: 27186886
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Immunity. 2016 May 17;44(5):1052-68
pubmed: 27192569
N Engl J Med. 2003 Oct 2;349(14):1324-32
pubmed: 14523140
J Virol. 2000 Nov;74(21):10249-55
pubmed: 11024158
F1000Res. 2017 May 26;6:748
pubmed: 28663787
N Engl J Med. 1994 Apr 28;330(17):1185-91
pubmed: 8093146
Nat Rev Immunol. 2014 Nov;14(11):768-74
pubmed: 25257362
Arch Neurol. 2007 Jan;64(1):72-5
pubmed: 17210811
J Infect Dis. 2015 Sep 1;212(5):803-7
pubmed: 25722295
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Blood. 2004 Feb 15;103(4):1244-52
pubmed: 14576041
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Sci Transl Med. 2019 Jan 16;11(475):
pubmed: 30651320
J Virol. 2005 Jan;79(2):1296-307
pubmed: 15613356
Ann Neurol. 2011 Sep;70(3):515-8
pubmed: 21905083
PLoS Pathog. 2011 Oct;7(10):e1002328
pubmed: 22028659
Immunol Cell Biol. 2011 Mar;89(3):408-16
pubmed: 21301484
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Mech Ageing Dev. 2003 Apr;124(4):477-85
pubmed: 12714256
Annu Rev Pathol. 2006;1:375-404
pubmed: 18039120
Annu Rev Immunol. 2013;31:635-674
pubmed: 23330956
J Virol. 2001 Jun;75(12):5550-8
pubmed: 11356962
N Engl J Med. 1976 Jun 17;294(25):1355-9
pubmed: 177872
J Infect Dis. 2009 Nov 15;200(10):1611-5
pubmed: 19832115
Curr Top Microbiol Immunol. 2015;390(Pt 1):241-65
pubmed: 26424649
Nat Med. 1996 May;2(5):551-5
pubmed: 8616714
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
J Hepatol. 1999 Mar;30(3):353-8
pubmed: 10190714
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7
pubmed: 20615947
Curr Opin Virol. 2016 Oct;20:34-39
pubmed: 27591678
Nat Med. 1996 Aug;2(8):906-11
pubmed: 8705861
Oncoimmunology. 2013 Jan 1;2(1):e22590
pubmed: 23483821
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
Curr Opin Immunol. 2010 Apr;22(2):223-30
pubmed: 20207527

Auteurs

Bithi Chatterjee (B)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Yun Deng (Y)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Angelika Holler (A)

Institute of Immunity and Transplantation, Royal Free Campus, University College London, United Kingdom.

Nicolas Nunez (N)

Inflammation Research, Institute of Experimental Immunology, University of Zurich, Switzerland.

Tarik Azzi (T)

Division of Infectious Diseases and Hospital Epidemiology, Children's Research Center, University Children's Hospital Zurich, Switzerland.

Liliana Danusia Vanoaica (LD)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Anne Müller (A)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Hana Zdimerova (H)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Olga Antsiferova (O)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Andrea Zbinden (A)

Institute of Medical Virology, University of Zurich, Switzerland.

Riccarda Capaul (R)

Institute of Medical Virology, University of Zurich, Switzerland.

Johannes H Dreyer (JH)

Institute for Pathology, Unfallkrankenhaus Berlin, Berlin, Germany.

David Nadal (D)

Inflammation Research, Institute of Experimental Immunology, University of Zurich, Switzerland.

Burkhard Becher (B)

Inflammation Research, Institute of Experimental Immunology, University of Zurich, Switzerland.

Mark D Robinson (MD)

Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
SIB Swiss Institute of Bioinformatics, Zurich, Switzerland.

Hans Stauss (H)

Institute of Immunity and Transplantation, Royal Free Campus, University College London, United Kingdom.

Christian Münz (C)

Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH